What question did this study set out to answer?

This analysis aims to evaluate the efficacy and safety of wilate prophylaxis specifically in patients with type 3 von Willebrand disease.

February 2, 2026European Journal Of Haematology

Efficacy and Safety of Prophylaxis With a Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease—A WIL‐31 Study Sub‐Analysis

View Full Paper

Ask AI

Bookmark

Authors

CKClaudia Djambas KhayatSaint Joseph University LDLeonid DubeyLviv City Children's Hospital AIAdlette Inati

Discussion

Member takes

Implication

Subgroup analysis reveals effective prophylaxis reduces bleeding rates in type 3 von Willebrand disease patients, suggesting significant clinical benefits.

Key Points

This analysis aims to evaluate the efficacy and safety of wilate prophylaxis specifically in patients with type 3 von Willebrand disease.
Patients received 20–40 IU/kg wilate prophylaxis 2–3 times weekly for 12 months.
Bleeding rates were measured during on-demand and prophylaxis phases.
The annualized bleeding rate (ABR) reduced from 37.1 to 5.2 during prophylaxis, an 86% reduction.
Most bleeds (95%) were minor, with 40% occurring in the nose.
Spontaneous ABRs reduced from 26.5 to 2.8 for overall and 20.3 to 1.4 for treated cases during on-demand versus prophylaxis.

Cite This Study

Khayat et al. (2026) studied this question.

synapsesocial.com/papers/6980fde8c1c9540dea80f92b https://doi.org/10.1111/ejh.70117

View Full Paper

Ask AI

Bookmark

Implication

Subgroup analysis reveals effective prophylaxis reduces bleeding rates in type 3 von Willebrand disease patients, suggesting significant clinical benefits.

Efficacy and Safety of Prophylaxis With a Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease—A WIL‐31 Study Sub‐Analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy and Safety of Prophylaxis With a Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease—A WIL‐31 Study Sub‐Analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider